T. D. Lash et al. / Tetrahedron 63 (2007) 12343–12351
12349
4.2.16. 3,5-Tridecano-13,17-diethyl-2,8,12,18-tetrame-
thylporphyrin (14a). A solution of p-toluenesulfonic acid
monohydrate (230 mg) in methanol (5 mL) was added to
a stirred solution of 13a (200 mg, 0.452 mmol) and 3,30-
diethyl-4,40-dimethyl-2,20-dipyrrylmethane-5,50-dicarbalde-
hyde9c (6a, 124 mg, 0.433 mmol) in dichloromethane
(50 mL) and methanol (5 mL). After few minutes, a deep
red-orange solution was formed. The mixture was stirred
at room temperature overnight in the dark, and a saturated
solution of zinc acetate in methanol (4.5 mL) was then
added. The resulting solution was allowed to stir in the
dark for two more days at room temperature. The mixture
was washed successively with water (100 mL), 5% hydro-
chloric acid solution (2ꢂ100 mL), 5% ammonia solution
(100 mL), and water (100 mL). The organic solution was
evaporated under reduced pressure, and the residue chro-
matographed on grade III alumina, eluting with dichloro-
methane. The colored fractions were evaporated under
reduced pressure and further purified on a grade 3 silica
gel column, eluting with toluene. The red band was collected
and recrystallized from chloroform/methanol to give the title
porphyrin as mauve crystals (61 mg, 0.101 mmol, 23%), mp
276 ꢀC, dec; UV–vis (1% Et3N/CHCl3, free base): lmax
(log10 3) 407 (5.33), 505 (4.31), 540 (4.06), 574 (4.08),
627 (3.83) nm; UV–vis (1% TFA/CHCl3, dication): lmax
(log10 3) 394 (infl, 4.89), 414 (5.57), 557 (4.35), 598 (infl,
J¼7.6 Hz), 2.00 (2H, quintet, J¼8 Hz), 2.19–2.27 (2H, m),
2.51–2.59 (2H, m), 3.24–3.30 (4H, two overlapping triplets),
3.59 (3H, s), 3.649 (3H, s), 3.654 (3H, s), 3.66 (3H, s), 3.67
(3H, s), 3.71 (3H, s), 3.96–4.01 (2H, m), 4.32 (2H, t,
J¼7.8 Hz), 4.41 (2H, t, J¼7.8 Hz), 4.92–4.97 (2H, m),
1
9.24 (1H, s), 9.86 (1H, s), 10.05 (1H, s), 10.06 (1H, s); H
NMR (TFA/CDCl3): d ꢁ3.58 (1H, s), ꢁ3.32 (1H, s),
ꢁ3.22 (1H, s), ꢁ2.55 (1H, s), 1.48–1.63 (10H, m), 1.69
(2H, quintet, J¼7 Hz), 1.76 (2H, quintet, J¼7 Hz), 1.89
(2H, quintet, J¼7.0 Hz), 2.09 (2H, quintet, J¼7.0 Hz),
2.27–2.35 (2H, m), 2.59–2.67 (2H, m), 3.10 (2H, t,
J¼7.8 Hz), 3.15 (2H, t, J¼7.8 Hz), 3.43 (3H, s), 3.57 (3H,
s), 3.59 (6H, s), 3.61 (6H, s), 3.63–3.68 (2H, m), 4.36–
4.42 (4H, two overlapping triplets), 4.89–4.94 (2H, m),
9.07 (1H, s), 10.42 (1H, s), 10.43 (1H, s), 10.56 (1H, s);
13C NMR (TFA/CDCl3): d 12.0, 12.2, 14.0, 21.7, 25.1,
26.1, 26.3, 26.7, 26.9, 27.1, 27.2, 28.8, 29.5, 30.1, 31.5,
35.54, 35.58, 39.1, 52.7, 96.9, 98.6, 98.9, 124.3, 125.5,
138.3, 139.5, 139.6, 139.7, 139.87, 139.95, 140.2, 141.1,
141.5, 141.7, 142.1, 142.3, 142.8, 143.0, 144.5, 175.0.
HRMS (EI) calcd for C45H58N4O4: 718.4458, found:
718.4465. Anal. Calcd for C45H58N4O4: C, 75.17; H, 8.13;
N, 7.79. Found: C, 75.02; H, 8.28; N, 7.82.
4.2.18. 3,5-Tridecano-13,17-diethyl-2,7,8,12,18-pentameth-
ylporphyrin (14c). The title porphyrin was prepared from
13b (100 mg, 0.219 mmol) and dipyrrylmethane dialdehyde
6a9c (60 mg, 0.210 mmol) as described previously. Recrys-
tallization from chloroform/methanol afforded the desired
porphyrin as dark maroon crystals (42 mg, 0.068 mmol,
33%), mp 270 ꢀC, dec; UV–vis (1% Et3N/CHCl3, free
base): lmax (log10 3) 407 (5.45), 507 (4.45), 540 (4.19),
575 (4.19), 627 (3.95) nm; UV–vis (1% TFA/CHCl3, dica-
tion): lmax (log10 3) 417 (5.66), 561 (4.46), 602 (4.15) nm;
1H NMR (CDCl3, 25 ꢀC): d ꢁ2.86 (2H, br s), 1.45–1.63
(10H, m), 1.65–1.71 (2H, m), 1.73–1.80 (2H, m), 1.81–
1.86 (6H, two overlapping triplets), 1.8–2.0 (4H, m), 2.27
(2H, quintet, J¼8 Hz), 3.59 (3H, s), 3.60 (3H, s), 3.61 (6H,
s), 3.62 (3H, s), 3.96–4.06 (6H, m), 4.85–5.04 (1H, m),
5.14–5.32 (1H, m), 9.80 (1H, s), 10.05 (1H, s), 10.06 (1H,
1
4.02) nm; H NMR (CDCl3): d ꢁ3.13 (2H, br s), 1.5–1.65
(10H, m), 1.70–1.81 (4H, m), 1.84 (3H, t), 1.86 (3H, t),
1.82–1.93 (2H, m), 2.21–2.29 (2H, m), 2.53–2.61 (2H, m),
3.57 (3H, s), 3.64 (3H, s), 3.66 (3H, s), 3.72 (3H, s), 3.96–
4.02 (4H, m), 4.08 (2H, q, J¼7.6 Hz), 4.95–4.99 (2H, m),
1
9.25 (1H, s), 9.86 (1H, s), 10.05 (1H, s), 10.06 (1H, s); H
NMR (TFA/CDCl3): d ꢁ3.91 (1H, s), ꢁ3.64 (1H, s),
ꢁ3.48 (1H, s), ꢁ2.80 (1H, s), 1.48–1.64 (10H, m), 1.69
(3H, t, J¼7.8 Hz), 1.74 (3H, t, J¼7.8 Hz), 1.70–1.82 (4H,
m), 1.89 (2H, quintet, J¼7.0 Hz), 2.10 (2H, quintet,
J¼7.6 Hz), 2.27–2.35 (2H, m), 2.59–2.68 (2H, m), 3.44
(3H, s), 3.56 (3H, s), 3.59 (3H, s), 3.60 (3H, s), 3.64–3.69
(2H, m), 4.01–4.09 (4H, two overlapping quartets), 4.90–
4.95 (2H, m), 9.09 (1H, s), 10.31 (1H, s), 10.44 (1H, s),
10.45 (1H, s); 13C NMR (TFA/CDCl3): d 11.82, 11.84,
12.1, 14.0, 16.2, 16.3, 20.14, 20.16, 25.1, 26.1, 26.3, 26.7,
26.9, 27.1, 27.2, 28.9, 30.1, 311.5, 35.6, 39.1, 96.0, 98.4,
98.7, 124.2, 125.5, 138.2, 138.7, 138.8, 140.0, 140.1, 141.4,
141.5, 141.8, 141.9, 142.0, 143.1, 143.3, 144.0, 144.1,
144.3. HRMS (EI) calcd for C41H54N4: 602.4348, found:
602.4349; HRMS (FAB) calcd for C41H54N4+H: 603.4430,
found: 603.4407. Anal. Calcd for C41H54N4$1/4H2O:
C, 81.07; H, 9.04; N, 9.22. Found: C, 80.84; H, 9.00; N,
9.19.
1
s); H NMR (TFA/CDCl3): d ꢁ3.60 (1H, s), ꢁ3.53 (1H,
s), ꢁ2.69 (1H, s), ꢁ2.57 (1H, s), 0.96–1.48 (12H, m), 1.67
(3H, t, J¼7.6 Hz), 1.70 (3H, t, J¼7.6 Hz), 1.73–1.83 (4H,
m), 2.04 (2H, quintet, J¼7.6 Hz), 2.15–2.24 (2H, m),
2.48–2.56 (2H, m), 3.28 (3H, s), 3.30 (3H, s), 3.32 (3H, s),
3.42–3.47 (2H, m), 3.488 (3H, s), 3.493 (3H, s), 3.97 (4H,
q, J¼7.7 Hz), 4.92–4.96 (2H, m), 10.08 (1H, s), 10.248
(1H, s), 10.253 (1H, s); 13C NMR (TFA/CDCl3): d 11.7,
12.1, 12.2, 14.6, 16.18, 16.22, 20.0, 25.0, 26.0, 26.6, 26.7,
27.0, 28.8, 29.4, 29.9, 31.3, 33.8, 38.1, 94.8, 98.12, 98.15,
126.0, 133.3, 137.0, 138.6, 138.7, 141.0, 141.4, 141.5,
141.6, 142.4, 143.0, 143.5, 143.6, 143.75, 143.78. HRMS
(FAB) calcd for C42H56N4+H: 617.4587, found: 617.4570.
Anal. Calcd for C42H56N4$1/4H2O: C, 81.18; H, 9.16; N,
9.01. Found: C, 81.00; H, 9.36; N, 9.00.
4.2.17. 3,5-Tridecano-13,17-bis-(2-methoxycarbonyl-
ethyl)-2,8,12,18-tetramethylporphyrin (14b). Dipyrrole
13a (100 mg, 0.226 mmol) was condensed with dialdehyde
6b35 (86 mg, 0.214 mmol) under the foregoing conditions.
Recrystallization from chloroform/methanol gave porphyrin
(35 mg, 0.049 mmol, 23%) as purple crystals, mp 248 ꢀC,
dec; UV–vis (1% Et3N/CHCl3, free base): lmax (log10 3)
408 (5.36), 506 (4.30), 541 (4.01), 574 (4.04), 628
(3.74) nm; UV–vis (1% TFA/CHCl3, dication): lmax
(log10 3) 396 (infl, 4.88), 416 (5.58), 559 (4.29), 598 (infl,
4.2.19. 3,5-Tridecano-7,13,17-diethyl-2,8,12,18-tetrameth-
ylporphyrin (14d). Porphyrin 14d was prepared by the
same procedure from 13c (200 mg, 0.425 mmol) and dialde-
hyde 6a9c (116 mg, 0.405 mmol). Recrystallization with
chloroform/methanol yielded the title porphyrin as dark ma-
roon crystals (75 mg, 0.12 mmol, 29%), mp 235 ꢀC, dec;
UV–vis (1% Et3N/CHCl3, free base): lmax (log10 3) 408
1
3.89) nm; H NMR (CDCl3): d ꢁ3.18 (1H, s), ꢁ3.11 (1H,
s), 1.5–1.64 (10H, m), 1.68–1.82 (4H, m), 1.88 (2H, quintet,